GH Research PLC (NASDAQ:GHRS) Receives Average Rating of “Moderate Buy” from Analysts

GH Research PLC (NASDAQ:GHRS) has been assigned an average rating of “Moderate Buy” from the twelve ratings firms that are presently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell rating and ten have assigned a buy rating to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $45.00.

A number of research firms have issued reports on GHRS. Wells Fargo & Company started coverage on GH Research in a research report on Monday, July 27th. They issued an “overweight” rating and a $44.00 price target on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of GH Research in a research note on Friday, July 17th. Cantor Fitzgerald raised their target price on shares of GH Research from $35.00 to $40.00 and gave the company an “overweight” rating in a report on Friday, August 7th. Guggenheim lifted their price target on shares of GH Research from $34.00 to $40.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Finally, Citigroup reiterated an “outperform” rating on shares of GH Research in a report on Friday, May 15th.

GH Research Stock Performance

GH Research stock opened at $28.19 on Friday. The company’s 50 day simple moving average is $26.09 and its 200-day simple moving average is $20.55. The company has a market capitalization of $1.93 billion, a price-to-earnings ratio of -28.19 and a beta of 1.29. GH Research has a 1 year low of $11.83 and a 1 year high of $31.44.

GH Research (NASDAQ:GHRS) last posted its earnings results on Thursday, August 6th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.06. Equities analysts expect that GH Research will post -1.2 earnings per share for the current year.

More GH Research News

Here are the key news stories impacting GH Research this week:

• Positive Sentiment: HC Wainwright raised its EPS forecasts for GH Research’s fourth quarter of 2026 and full-year 2026, projecting losses of $0.31 and $1.14 per share, respectively, compared with previous estimates of $0.32 and $1.21. The firm maintained its Buy rating. GH Research analyst estimates
• Positive Sentiment: The analyst also slightly improved quarterly EPS estimates for the second, third and fourth quarters of 2027, reducing projected losses by $0.01 per share in each period. The full-year 2027 loss forecast was raised to $1.62 per share from $1.64.
• Neutral Sentiment: HC Wainwright initiated longer-term EPS estimates of losses totaling $1.76 per share for 2028, $2.11 for 2029 and $1.22 for 2030. These projections suggest continued operating losses for several years, despite expectations for gradual improvement by 2030.
• Negative Sentiment: GH Research is still expected to post a substantial loss, with the current-year consensus estimate near a $1.33-per-share deficit. The absence of near-term profitability may weigh on the stock, particularly after its strong advance toward its 52-week high.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of GHRS. Lynx1 Capital Management LP increased its position in GH Research by 27.5% during the third quarter. Lynx1 Capital Management LP now owns 8,601,189 shares of the company’s stock worth $122,997,000 after buying an additional 1,854,238 shares during the period. RTW Investments LP grew its position in shares of GH Research by 6.5% during the fourth quarter. RTW Investments LP now owns 5,933,815 shares of the company’s stock worth $75,359,000 after acquiring an additional 364,251 shares during the last quarter. Avoro Capital Advisors LLC purchased a new position in shares of GH Research during the fourth quarter worth approximately $22,860,000. Troluce Capital Advisors LLC increased its holdings in shares of GH Research by 165.4% in the 1st quarter. Troluce Capital Advisors LLC now owns 990,472 shares of the company’s stock valued at $13,926,000 after acquiring an additional 617,260 shares during the period. Finally, Millennium Management LLC raised its position in GH Research by 324.1% in the 3rd quarter. Millennium Management LLC now owns 863,602 shares of the company’s stock valued at $12,350,000 after purchasing an additional 659,957 shares during the last quarter. Institutional investors and hedge funds own 56.90% of the company’s stock.

GH Research Company Profile

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.